Study to Evualate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants with B-Cell Malignancies

This study aims to understand how a medication called ABBV-101 reacts in adults with certain types of non-Hodgkin Lymphomas, including Waldenstrom’s macroglobulinaemia.
Researchers are looking to see how effective the drug is, as well as what the best dose is. The study is split into two parts, and people with WM who meet other criteria are eligible for the first phase of the trial where researchers are measuring what the highest dose could be.
ABBV-101 is a type of drug known as a BTK-degrader which targets certain proteins that help cancer cells grow. Not much is yet known about ABBV-101 and so it’s not known how people on the trial will react to it, or how effective it will be. However, the results will give researchers a lot of information to take forward, meaning it might help many people in the future.